Beginning to understand high-density lipoproteins.

Abstract

This article reconciles the classic view of high-density lipoproteins (HDL) associated with low risk for cardiovascular disease (CVD) with recent data (genetics studies and randomized clinical trials) casting doubt over the widely accepted beneficial role of HDL regarding CVD risk. Although HDL cholesterol has been used as a surrogate measure to investigate HDL function, the cholesterol content in HDL particles is not an indicator of the atheroprotective properties of HDL. Thus, more precise measures of HDL metabolism are needed to reflect and account for the beneficial effects of HDL particles. Current and emerging therapies targeting HDL are discussed.

• Authors: Carlos G Santos-Gallego, Juan J Badimon, Robert S Rosenson
• Journal: Endocrinology and metabolism clinics of North America (Endocrinol Metab Clin North Am) Vol. 43 Issue 4 Pg. 913-47 (Dec 2014) ISSN: 1558-4410 [Electronic] United States
• PMID: 25432389 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Apolipoprotein A-I
• Biomarkers
• Lipoproteins, HDL

Topics

• Apolipoprotein A-I (chemistry, metabolism)
• Biomarkers (metabolism)
• Cardiovascular Diseases (metabolism, therapy)
• Humans
• Lipoproteins, HDL (chemistry, metabolism)
• Metabolic Networks and Pathways (physiology)